BCI Pharma was set up in March 2013.
The two founders have extensive expertise in discovery and patient treatment.
Dr. Dominique Surleraux was head of research for a pharmaceutical company (J&J) and two biotech companies (Idenix and Tibotec). Dr. Elisabeth Picou had a position in a hospital, treating patients with infectious diseases.
Our company is a Contract Research Organisation offering services and innovative products (new chemotypes) to increase the efficacy of drug discovery and ensure strong a intellectual property position and a low attrition rate.
Our kinase platform is based on a new chemotype with excellent phys-chem properties, able to explore a new chemical space and as such very promising for treating CNS, inflammation, cancer and metabolic diseases.